NCT04542590View on ClinicalTrials.gov

Natural History of Patients With PH3 and a History of Stone Events

CompletedOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

July 23, 2024

Study Completion Date

July 23, 2024

Conditions
Primary Hyperoxaluria Type 3
Trial Locations (6)

10016

Clinical Trial Site, New York

69120

Clinical Trial Site, Heidelberg

02115

Clinical Trial Site, Boston

M5G 1X8

Clinical Trial Site, Toronto

04-141

Clinical Trial Site, Warsaw

WC1N 3JH

Clinical Trial Site, London

All Listed Sponsors
lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY

NCT04542590 - Natural History of Patients With PH3 and a History of Stone Events | Biotech Hunter | Biotech Hunter